Breakthrough study discovers 6 changing faces of 'global killer' bacteria

Researchers unlock vital new information to improve vaccinations against pneumococcus infection

02-Oct-2014 - Every ten seconds a human being dies from Streptococcus pneumoniae infection, also known as pneumococcus, making it a leading global killer. An interdisciplinary team of researchers from the University of Leicester in collaboration with international experts have unlocked a genetic switch ...

New EMA guidance on development of antibacterials

11-Nov-2013 - The European Medicines Agency (EMA) released an addendum to the guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections. One of the most important aspects of the addendum is that it outlines a new approach facilitating the development of antibacterial ...

Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients

One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting

07-Jun-2010 - Sanofi-aventis reported new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from ...

Scientists Crack the Gingivitis Genetic Code for First Time

Study Shows Nearly One-Third of Human Genome is Involved in Gingivitis

11-Dec-2009 - For the first time, US scientists have successfully identified gene expression and biological pathways involved in the onset and healing process of gingivitis, a condition affecting more than 50% of the UK adult population, and which if left untreated, can potentially lead to heart disease, ...

Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate in Fibromyalgia

Preliminary Top Line Results of Phase III Trial Show Significant Decreases in Pain and Fatigue and Improved Daily Function in Fibromyalgia Patients

24-Nov-2008 - Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the first of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its key endpoints, demonstrating that ...

Genentech and Biogen Idec Announce Positive Results from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis

30-Aug-2006 - Genentech, Inc. and Biogen Idec, Inc. announced that a Phase II study of Rituxan® (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions ...

BioVeris Completes Agreements With University of Massachusetts at Amherst

27-May-2005 - BioVeris Corporation announced that it has entered into an option agreement with the University of Massachusetts at Amherst (UMA) for exclusive patent rights to a unique vaccine candidate for Chlamydia, the most frequently reported infectious disease in the United States. Under the agreement with ...

OctoPlus and Leiden University Medical Center to start patient trials with novel drug against chronic middle ear infection

19-Jan-2004 - An innovative drug against chronic middle ear infection will go into patient trials shortly in Leiden, The Netherlands. Drug delivery and development company OctoPlus and the Leiden University Medical Centre (LUMC) have joined forces in this clinical trial, with OctoPlus taking responsibility for ...

Biotechnology Breakthrough for Asthma

FDA approves Xolair, the first humanized antibody to target IgE, responsible for asthma with an allergic component

24-Jun-2003 - Genentech, Inc.Novartis Pharmaceuticals Corporation and Tanox, Inc. announced that the novel IgE-blocker Xolair® (Omalizumab) for subcutaneous use has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe persistent asthma in adults and adolescents. ...